Andrea Lisco

Dr. Andrea Lisco

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JLJean K. Lim
Jean K. Lim
ALAndrea Lisco
Andrea Lisco
DMDavid H. McDermott
David H. McDermott
LHLinda Huynh
Linda Huynh
JWJerrold M. Ward
Jerrold M. Ward
PMPhilip M. Murphy
Philip M. Murphy
West Nile virus (WNV) is a re-emerging pathogen that can cause fatal encephalitis. In mice, susceptibility to WNV has been reported to result from a single point mutation in oas1b, which encodes 2′–5′ oligoadenylate synthetase 1b, a member of the type I interferon-regulated OAS gene family involved in viral RNA degradation. In man, the human ortholog of oas1b appears to be OAS1. The ‘A’ allele at SNP rs10774671 of OAS1 has previously been shown to alter splicing of OAS1 and to be associated with reduced OAS activity in PBMCs. Here we show that the frequency of this hypofunctional allele is increased in both symptomatic and asymptomatic WNV seroconverters (Caucasians from five US centers; total n = 501; OR = 1.6 [95% CI 1.2–2.0], P = 0.0002 in a recessive genetic model). We then directly tested the effect of this SNP on viral replication in a novel ex vivo model of WNV infection in primary human lymphoid tissue. Virus accumulation varied markedly among donors, and was highest for individuals homozygous for the ‘A’ allele (P<0.0001). Together, these data identify OAS1 SNP rs10774671 as a host genetic risk factor for initial infection with WNV in humans. When humans are exposed to infectious agents, the outcome may vary: some remain uninfected, some who become infected remain asymptomatic, and symptomatic individuals may develop clinical manifestations that vary in number and severity. Both host and environmental factors are thought to influence outcome. Here we show that a specific human mutation that results in reduced function in a known antiviral gene named OAS1 is associated with increased rate of infection with West Nile virus, a member of the flavivirus family. OAS1 codes for a component of the type I interferon signaling system; its homologue in mice has been shown previously to be important for flavivirus susceptibility. Individuals carrying two copies of the hypofunctional variant of OAS1 were found more frequently than expected among both asymptomatic and symptomatic WNV-positive individuals. To investigate further, we developed a novel model of WNV replication using human tonsil tissue in which high variability in replication was observed among donors. We found that the highest virus accumulation occurred in donors with two copies of the hypofunctional OAS1 variant. Together these data suggest that OAS1 activity may influence the probability of initial infection, but not the severity or symptomatic quality of infection, after WNV exposure in man.

23 March 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NMNiki M Moutsopoulos
Niki M Moutsopoulos
CZChrista S Zerbe
Christa S Zerbe
TWTeresa Wild
Teresa Wild
NDNicolas Dutzan
Nicolas Dutzan
LBLaurie Brenchley
Laurie Brenchley
SHSteven M Holland
Steven M Holland
A patient with leukocyte adhesion deficiency type 1 (LAD1) had severe periodontitis and an intractable, deep, nonhealing sacral wound. We had previously found a dominant interleukin-23–interleukin-17 signature at inflamed sites in humans with LAD1 and in mouse models of the disorder. Blockade of this pathway in mouse models has resulted in resolution of the immunopathologic condition. We treated our patient with ustekinumab, an antibody that binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the activity of these cytokines, inhibiting interleukin-23–dependent production of interleukin-17. After 1 year of therapy, our patient had resolution of his inflammatory lesions without serious infections or adverse reactions. Inhibition of interleukin-23 and interleukin-17 may have a role in the management of LAD1. (Funded by the National Institute of Allergy and Infectious Diseases and others.)

8 February 2007 in Blood
Verified
Journal Article
Closed access
PDF file
ABAngélIque Biancotto
AngélIque Biancotto
JGJean-Charles Grivel
Jean-Charles Grivel
SISarah J. Iglehart
Sarah J. Iglehart
CVChristophe Vanpouille
Christophe Vanpouille
ALAndrea Lisco
Andrea Lisco
MLMichael M. Lederman
Michael M. Lederman
There is growing recognition that HIV-1 infection leads to an activation of the immune system that includes perturbations of cytokine expression, redistribution of lymphocyte subpopulations, cell dysfunction, and cell death. Here, we explored the relationships between HIV-1 infection and immune activation in chronically HIV-1–infected human lymph nodes. In addition to CD4 T-cell depletion, we found increased effector T-cell frequencies associated with profound up-regulation of an activation marker CD38 in naive, central memory, and effector CD4+ and CD8+ T cells. Likewise, Fas death receptor (CD95) was more frequently detectable on T cells from HIV-1 nodes. Dendritic cell (DC) depletion was dramatic, with plasmacytoid DCs (PDCs) 40-fold and myeloid DCs (MDCs) 20-fold less frequent in HIV+ nodes than in control nodes. Cytokine dysregulation was evident, with IL-2 and IL-15 as much as 2 or 3 logs greater in infected nodes than in control nodes. Thus, activated effector cells are inappropriately attracted and/or retained in lymphoid tissue in chronic HIV-1 infection. High-level cytokine expression in turn activates and retains more cells at these sites, leading to lymphadenopathy and massive bystander activation that characterizes HIV-1 infection. Strategies targeting these activation pathways may lead to new therapies.

10 February 2010 in Mucosal Immunology
Verified
Journal Article
Closed access
PDF file
ESE Saba
E Saba
JGJ-C Grivel
J-C Grivel
CVC Vanpouille
C Vanpouille
BBB Brichacek
B Brichacek
WFW Fitzgerald
W Fitzgerald
ALAndrea Lisco
Andrea Lisco

15 January 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JLJean K. Lim
Jean K. Lim
DMDavid H. McDermott
David H. McDermott
ALAndrea Lisco
Andrea Lisco
GFGregory A. Foster
Gregory A. Foster
DKDavid Krysztof
David Krysztof
PMPhilip M. Murphy
Philip M. Murphy
Background. West Nile virus (WNV) is a neurotropic flavivirus transmitted to humans by mosquito vectors. Homozygosity for CCR5Δ32, a complete loss-of

15 January 2008 in Blood
Verified
Journal Article
Open access
PDF file
ABAngélique Biancotto
Angélique Biancotto
SISarah J. Iglehart
Sarah J. Iglehart
CVChristophe Vanpouille
Christophe Vanpouille
CCCristian E. Condack
Cristian E. Condack
ALAndrea Lisco
Andrea Lisco
JGJean-Charles Grivel
Jean-Charles Grivel
We demonstrate mechanisms by which HIV-1 appears to facilitate its own infection in ex vivo–infected human lymphoid tissue. In this system, HIV-1 readily infects various CD4+ T cells, but productive viral infection was supported predominantly by activated T cells expressing either CD25 or HLA-DR or both (CD25/HLA-DR) but not other activation markers: There was a strong positive correlation (r = 0.64, P = .001) between virus production and the number of CD25+/HLA-DR+ T cells. HIV-1 infection of lymphoid tissue was associated with activation of both HIV-1–infected and uninfected (bystanders) T cells. In these tissues, apoptosis was selectively increased in T cells expressing CD25/HLA-DR and p24gag but not in cells expressing either of these markers alone. In the course of HIV-1 infection, there was a significant increase in the number of activated (CD25+/HLA-DR+) T cells both infected and uninfected (bystander). By inducing T cells to express particular markers of activation that create new targets for infection, HIV-1 generates in ex vivo lymphoid tissues a vicious destructive circle of activation and infection. In vivo, such self-perpetuating cycle could contribute to HIV-1 disease.